αααααβααΎαNVV1 β’ FRA
add
Novavax Inc
10.86β¬
10 ααααααΆ, 4:08:54 PM ααααβααα +2 · EUR · FRA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
DEααΆαααΈααααΆααααΆααααααΆααα
α’αΆαααα·α
αα·αααΈαα»α
11.02β¬
α
αααααααααααα
10.86β¬ - 10.86β¬
α
ααααααα½αααααΆαα
α»αααααα
3.38β¬ - 23.93β¬
ααΎαβαα»αβααΈααααΆα
1.66Β αααΈααΆα USD
ααα ααα½αααΌαααααα
13.13Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NASDAQ
αααα»αβααααααΆαβ
Yahoo Finance
1 ααααβαα»α
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
0.084%
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | ααΈααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 93.86Β ααΆα | 15.94% |
α
αααΆαααααα·ααααα·ααΆα | 82.30Β ααΆα | -26.87% |
α
αααΌααα»ααα | -147.55Β ααΆα | 49.80% |
ααααΆααα
αααααα»ααα | -157.21 | 56.70% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -1.05 | 69.21% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -126.58Β ααΆα | 58.32% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -1.56% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | ααΈααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 480.59Β ααΆα | -23.10% |
ααααααααα»α | 1.35Β αααΈααΆα | -12.26% |
ααΆαααα½ααα»αααααΌαααα»α | 2.22Β αααΈααΆα | -8.93% |
ααΌαβααααα»α | -867.08Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 140.40Β ααΆα | β |
ααααααααααΉαααααα
| -1.78 | β |
ααα
ααααααΎαααααα | -22.01% | β |
ααα
ααααααΎααΎααα»α | 96.03% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | ααΈααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -147.55Β ααΆα | 49.80% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -83.56Β ααΆα | 74.34% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -7.25Β ααΆα | 69.22% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 5.89Β ααΆα | 101.66% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -87.87Β ααΆα | 87.66% |
ααα αΌαααΆα
αααααΆααααααα | -552.90Β ααΆα | -64.08% |
α’αααΈ
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
ααΆααααααΎαα‘αΎα
1987
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
1,543
